COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) AND EMPHYSEMA

Drug development companies are regularly contacting us to take part in new clinical trials for improved COPD treatments, and we are keen to do so, as this provides Western Australians with COPD the opportunity to access new treatments.

If you suffer from COPD and would like to be considered for enrolment for participation in a clinical trials, please contact us by telephoning 9346 4964, email This e-mail address is being protected from spambots. You need JavaScript enabled to view it or click here to register online.

Study outline	Recruitment status
CNVA237AAU01: A 15 week multicentre trial comparing the efficacy, tolerability and safety of NVA237 medication compared to tiotropium added on to fluticasone/salmeterol in patients with COPD	Recruiting now!
A6631029: A 12 week long study to learn about the effects and safety of the study drug. The medication is a tablet to be taken daily andacts to reduce inflammation in the lungs of patients with COPD. 9 visits over approx 18 weeks. This is an international study.	Recruiting closed
P05575 - A 2-year dose-range finding, adaptive-design study of the effects of SCH527123 in subjects with moderate to severe COPD.	Recruiting closed
HZC102871 - A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the annual rate of exacerbations in subjects with COPD.	Recruiting closed
PT003003 –To assess the cardiac safety of a novel combination and delivery mechanism for an inhaled medication.	Recruiting closed
CQVA149A2303: A 26-week treatment multi-center, randomized, double-blind, parallel group, placebo and active controlled (open label) study to assess the efficacy safety and tolerability of QVA149 (110/50 mcg q.d.) in patients with moderate to severe COPD.	Recruiting closed
DB2113774: A multicentre trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 and with tiotropium over 24 weeks in subjects with COPD	Recruiting closed